Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview;Therapie kognitiver defizite durch AChE-hemmer bei patienten mit schizophrenie. Eine systematische übersicht

Nervenarzt

Volumn 79, Issue 1, 2008, Pages 47-59

  Voss B ^a   Thienel, R ^a   Leucht, S ^b   Kircher, T ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acetylcholinesterase inhibitors; Cholinergic system; Cognitive deficits; Schizophrenia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NICOTINIC RECEPTOR; PHYSOSTIGMINE; RIVASTIGMINE;

CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG MECHANISM; HUMAN; MEDICAL RESEARCH; META ANALYSIS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; GALANTAMINE; HUMANS; INDANS; PHENYLCARBAMATES; PHYSOSTIGMINE; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 38349170971     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2358-1     Document Type: Review

References (90)

1. Addington J, Addington D (1999) Neurocognitive and social functioning in schizophrenia. Schizophr Bull 25: 173-182
2. Adler LE, Hoffer LD, Wiser A et al. (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-1861
3. Bilder RM, Goldman RS, Robinson D et al. (2000) Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 157: 549-559
4. Bora E, Veznedaroglu B, Kayahan B (2005) The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 28: 139-141
5. Breese CR, Lee MJ, Adams CE et al. (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364
6. Buchanan RW, Summerfeld A, Tek C, Gold J (2001) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59: 29-33
7. Bymaster FP, Felder C, Ahmed S, McKinzie D (2002) Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1: 163-181
8. Cannon TD, Bearden CE, Hollister JM et al. (2000) Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull 26: 379-393
9. Callicott JH, Egan MF, Mattay VS et al. (2003) Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 160: 709-719
10. Chen WJ, Liu SK, Chang CJ et al. (1998) Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry 155: 1214-1220
11. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001) Decreased muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8,9,10 and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158: 918-925
12. Cummings JL (2000) Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 157: 4-15
13. Davis KL, Mohs RC, Tinklenberg JR et al. (1978) Physostigmine: improvement of long-term memory processes in normal humans. Science 201: 272-274
14. Deutsch SI, Rosse RB, Schwartz BL et al. (2005) Therapeutic implications of a selective alpha7 nicotinic receptor abnormality in schizophrenia. Isr J Psychiatry Relat Sci 42: 33-44
15. Dickerson B (2006) Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment. Curr Opin Psychiatry 19: 229-306
16. Eberhard J, Riley F, Levander S (2003) Premorbid IQ and schizophrenia. Increasing cognitive reduction by episodes. Eur Arch Psychiatry Clin Neurosci 253: 84-88
17. Freedman R, Adams CE, Leonard S (2000) The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 20: 299-306
18. Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22-33
19. Freudenreich O, Herz L, Deckersbach T et al. (2005) Added donepezil for stable schizophrenia: a double-blind pacebo-controlled trial. Psychopharmacology 181: 358-363
20. Friedman JI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 174: 45-53
21. Friedman JI, Adler DN, Howanitz E et al. (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51: 349-357
22. Furey ML, Pietrini P, Haxby JV (2000) Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 290: 2315-2319
23. Grimm U, Moser U, Mutschler E, Lambrecht G (1994) Muscarinic receptors: focus on presynaptic mechanisms and recently developed novel agonists and antagonists. Pharmazie 49: 711-726
24. Gold S, Arndt S, Nopoulos P et al. (1999) Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 156: 1342-1348
25. Harris JG, Kongs S, Allensworth D et al. (2004) Effects of nicotine on cognitive defizits in schizophrenia. Neuropsychopharmacology 29: 1378-1385
26. Harvey PD, Keefe RS (2001) Studies of cognitive change in ptients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158: 176-184
27. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficits in schizophrenia: A quantitative review of the evidence. Neuropsychology 12: 426-445
28. Heydebrand G (2006) Cognitive deficits in the families of patients with schizophrenia. Curr Opin Psychiatry 19: 227-281
29. Hoff AL, Riordan H, O'Donnell DW et al. (1992) Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 149: 898-903
30. Hoff AL, Sakuma M, Wieneke M et al. (1999) Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 156: 1336-1341
31. Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 147: 1-46
32. Hughes JR, Hatsukami KD, Mitchell JE et al. (1986) Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 152: 993-997
33. Hutton SB, Puri BK, Duncon LJ et al. (1998) Executive function in first-episoed schizophrenia. Psychol Med 28: 463-473
34. Hyde TM, Crook JM (2001) Cholinergic systems and schizophrenia: primary pathology or epiphenoma? J Chem Neuroanat 22: 53-63
35. Ichikawa J, Dai J, O'Laughlin A et al. (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26: 325-339
36. Jann MW (2004) Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24: 1759-1783
37. Karson CN, Mrak RE, Husain MM, Griffin WS (1996) Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 29: 181-191
38. Keefe SE, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review an meta-analysis. Schizophr Bull 25: 201-222
39. Keefe RS, Young CA, Rock SL et al. HGGN Study Group (2006) One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81: 1-15
40. Keefe SE, Seidman LJ, Christensen BK et al. (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized double-blind trial of Olanzapine versus low doses of Haloperidol. Am J Psychiatry 161: 985-995
41. Keri S, Janka Z (2004) Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand 110: 83-91
42. Kirrane RM, Mitropoulou V, Nunn M et al. (2001) Physostigmine and cognition in schizotypal personality disorder. Schizophr Res 48: 1-5
43. Kitawaga H, Takenouchi T, Azuma R et al. (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28: 542-551
44. Kivircik Akdede BB, Alptekin K, Kitis A et al. (2004) Effects of quetiapine on cognitive functions in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 233-238
45. Lenzi A, Tuscano D (2004) Do Acetylcholinesterase inhibitors have a role in improving cognitive impairment in patients with schizophrenia? Int J Pharm Med 18: 139-148
46. Lenzi A, Maltini E, Poggi E et al. (2003) Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol 6: 317-321
47. Levin ED (2002) Nicotinic receptor subtypes and cognitive function. J Neurobiol 53: 633-640
48. Levin ED, McClernon FJ, Rezvani AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184: 523-539
49. Lewin JS, Friedman L, Wu D et al. (1996) Cortical localization of human sustained attention: detection with functional MR using a visual vigilance paradigm. J Comput Assist Tomogr 20: 695-701
50. Malhotra AK, Litman RE, Pickar D (1993) Adverse effects of antipsychotic drugs. Drug Saf 9: 429-436
51. Mansvelder HD, Aerde KI van, Couey JJ, Brussaard AB (2006) Nicotinic modulation of neural networks: from receptors to cognition. Psychopharmacology 184: 292-305
52. Martin LF, Kem WR, Freedman R (2004) Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174: 54-64
53. Medalia A, Lim RW (2004) Self-awareness of cognitive functioning in schizophrenia. Schizophr Res 71: 331-338
54. Mendelsohn E, Rosenthal M, Bohiri Y et al. (2004) Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-labeled study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol 19: 319-324
55. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255
56. Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55: 1013-1022
57. Mohamed S, Paulsen JS, O'Leary D et al. (1999) Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 56: 749-754
58. Morrison G, O'Carroll R, McCreadie R (2006) Long-term course of cognitive impairment in schizophrenia. Br J Psychiatry 189: 556-557
59. Nahas Z, George MS, Horner MD et al. (2003) Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase 9: 274-282
60. Peuskens J, Demily C, Thibaut F (2005) Treatment of cognitive dysfunction in schizophrenia. Clin Ther 27: 25-37
61. Powchik P, Davidson M, Haroutunian V et al. (1998) Postmortem studies in schizophrenia. Schizophr Bull 24: 325-341
62. Raskind MA, Perskind ER, Wessel T, Yuan W (2000) Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261-2268
63. Reyes JF, Preskorn SH, Khan A et al. (2004) Concurrent administration of donepezil HCI and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol 58: 50-57
64. Rezvani AH, Levin ED (2001) Cognitive effects of nicotine. Biol Psychiatry 49: 258-267
65. Riley EM, McGovern D, Mockler D et al. (2000) Neuropsychological functioning in first-episode psychosis - evidence of specific deficits. Schizophr Res 43: 47-55
66. Ripoll N, Bronnec M, Bourin M (2004) Nicotinic receptors and schizophrenia. Curr Med Res Opin 20: 1057-1074
67. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Donepezil Study Group (1998) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 158: 1021-1031
68. Rogers SL, Doody RS, Pratt RD et al. (2000) Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of US multicenter open-label study. Eur Neuropsychopharmacol 10: 195-203
69. Rosse BR, Deutsch SI (2002) Adjuvant Galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25: 272-275
70. Sacco KA, Termine A, Seyal A et al. (2005) Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62: 649-659
71. Samochicki M, Höffle A, Fehrenbacher A et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305: 1024-1036
72. Santos MD, Alkondon M, Pereira EFR et al. (2002) The nicotinic allosteric potentiating ligand Galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61: 1222-1234
73. Schubert MH, Keith AY, Hicks PB (2006) Galantamine improves cognition in schizophrenic patients stabilized on Risperidone. Biol Psychiatry 60: 530-533
74. Schwartz JT, Brotman AW (1992) A clinical guide to antipsychotic drugs. Drugs 44: 981-992
75. Saykin AJ, Shtasel DL, Gur RE et al. (1994) Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124-131
76. Sharma T, Reed C, Aasen I, Kumari V (2006) Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr Res 85: 73-83
77. Sing A, Potter A, Newhouse P (2004) Nicotinic acetylcholine receptor system and neuropsychiatric disorders. Drugs 7: 1096-1103
78. Smith RC, Singh A, Infante M et al. (2002) Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27: 479-497
79. Stip E, Chouinard S, Boulay LJ (2005) On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 219-232
80. Stip E, Sepehry AA, Prouteau A et al. (2005) Cognitive discernible factors between schizophrenia and schizoaffective disorder. Brain Cogn 59: 292-295
81. Stirling J, White C, Lewis S et al. (2003) Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow up of an epidemiological cohort-sectional analysis. Psychiatry Res 121: 219-227
82. Stryjer R, Strous RD, Bar F et al. (2003) Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 26: 12-17
83. Sullivan EV, Shear PK, Zipursky RB et al. (1994) A deficit profile of executive, memory and motor functions in schizophrenia. Biol Psychiatry 36: 641-653
84. Tandon R, Shipley JE, Greden JG et al. (1991) Muscarinic cholinergic hyperactivity in schizophrenia: relationship to positive and negative symptoms. Schizophr Res 4: 23-30
85. Tandon R (2002) Safety and tolerability: how do newer generation.,atypical" antipsychotics compare? Psychiatr Q 73: 297-311
86. Texido L, Ros E, Martin-Satue M et al. (2005) Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 145: 672-678
87. Tugal Ö, Yazici KM, Yagcioglu AEA, Gögüs A (2004) A double-blind, placebo-controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 7: 117-123
88. Turetsky B, Moberg PJ, Mozley LH et al. (2002) Memory-delineated subtypes of schizophrenia: Relationship to clinical, neuroanatomical and neurophysiological measures. Neuropsychology 16: 481-490
89. Üneri Ö, Tural Ü, Cakin Memik N (2006) Smoking and schizophrenia: Where is the biological connection? Turk J Psychiatry 17: 1-10
90. Woodruff-Pak DS, Lander C, Geerts H (2002) Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 8: 405-426